Cost-effectiveness of Resonance® metallic ureteral stent compared with standard polyurethane ureteral stents in malignant ureteric obstruction: A cost-utility analysis

IF 1.6 Q3 UROLOGY & NEPHROLOGY BJUI compass Pub Date : 2024-03-20 DOI:10.1002/bco2.332
Dawn M. Cooper, Rachel Lines, Iqbal Shergill
{"title":"Cost-effectiveness of Resonance® metallic ureteral stent compared with standard polyurethane ureteral stents in malignant ureteric obstruction: A cost-utility analysis","authors":"Dawn M. Cooper,&nbsp;Rachel Lines,&nbsp;Iqbal Shergill","doi":"10.1002/bco2.332","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Malignant ureteral obstruction (MUO) is a frequent challenge for urologists. Patients have poor prognoses, treatment aims to improve quality-of-life while optimising renal function. Standard practice in the United Kingdom is to use polyurethane stents, which require frequent surgical replacements for blockages and encrustation. More durable metallic stents are available, although these incur an increased initial purchase price.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>We aim to assess whether the use of polyurethane double-J (JJ) or metallic stent, Resonance® is more cost-effective for managing MUO in the UK healthcare setting.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A Markov model was parameterised to 5 years with costs and health-related quality-of-life consequences for treating MUO with Resonance metallic stent (Cook Medical), versus standard JJ stents, from the UK care system perspective, with 3.5% discounting. Deterministic and probabilistic sensitivity analyses were undertaken to assess the effect of uncertainty.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Over 5 years, approximately four fewer repeat surgical interventions were estimated in the metallic stent arm compared with the JJ stent, driving a 23.4% reduction in costs. The mean estimates of costs and benefits indicate that treatment of MUO with Resonance for 5 years is dominant over JJ stents. Over 5 years a cost-saving of £2164.74 and a health gain of +0.046 quality-adjusted life years (QALYs) per patient is estimated. With a maximum willingness to pay of £20 k per QALY, a net monetary benefit (NMB) of £3077.83 is estimated. Probabilistic sensitivity analysis at a willingness to pay threshold of £20 000 indicates an 89.3% probability of Resonance being cost-effective over JJ stents. Within 1-year savings of £726.53 are estimated driven by a reduction of two fewer repeat surgical interventions when using the metallic stent.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Resonance metallic stents for the treatment of MUO reduce the number of repeat procedures and could be a cost-effective option for the treatment, potentially offering efficiencies to the healthcare system.</p>\n </section>\n </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 5","pages":"465-475"},"PeriodicalIF":1.6000,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.332","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJUI compass","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bco2.332","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Malignant ureteral obstruction (MUO) is a frequent challenge for urologists. Patients have poor prognoses, treatment aims to improve quality-of-life while optimising renal function. Standard practice in the United Kingdom is to use polyurethane stents, which require frequent surgical replacements for blockages and encrustation. More durable metallic stents are available, although these incur an increased initial purchase price.

Aims

We aim to assess whether the use of polyurethane double-J (JJ) or metallic stent, Resonance® is more cost-effective for managing MUO in the UK healthcare setting.

Methods

A Markov model was parameterised to 5 years with costs and health-related quality-of-life consequences for treating MUO with Resonance metallic stent (Cook Medical), versus standard JJ stents, from the UK care system perspective, with 3.5% discounting. Deterministic and probabilistic sensitivity analyses were undertaken to assess the effect of uncertainty.

Results

Over 5 years, approximately four fewer repeat surgical interventions were estimated in the metallic stent arm compared with the JJ stent, driving a 23.4% reduction in costs. The mean estimates of costs and benefits indicate that treatment of MUO with Resonance for 5 years is dominant over JJ stents. Over 5 years a cost-saving of £2164.74 and a health gain of +0.046 quality-adjusted life years (QALYs) per patient is estimated. With a maximum willingness to pay of £20 k per QALY, a net monetary benefit (NMB) of £3077.83 is estimated. Probabilistic sensitivity analysis at a willingness to pay threshold of £20 000 indicates an 89.3% probability of Resonance being cost-effective over JJ stents. Within 1-year savings of £726.53 are estimated driven by a reduction of two fewer repeat surgical interventions when using the metallic stent.

Conclusions

Resonance metallic stents for the treatment of MUO reduce the number of repeat procedures and could be a cost-effective option for the treatment, potentially offering efficiencies to the healthcare system.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Resonance® 金属输尿管支架与标准聚氨酯输尿管支架在恶性输尿管梗阻中的成本效益比较:成本效益分析
恶性输尿管梗阻(MUO)是泌尿科医生经常面临的挑战。患者预后较差,治疗的目的是改善生活质量,同时优化肾功能。英国的标准做法是使用聚氨酯支架,这种支架需要经常进行手术更换,以防堵塞和结壳。我们的目的是评估在英国的医疗环境中,使用聚氨酯双J(JJ)支架还是Resonance®金属支架治疗MUO更具成本效益。从英国医疗系统的角度出发,使用Resonance金属支架(Cook Medical公司)治疗MUO与使用标准JJ支架治疗MUO的成本和与健康相关的生活质量后果的马尔可夫模型参数化为5年,贴现率为3.5%。为了评估不确定性的影响,我们进行了确定性和概率敏感性分析。在5年时间里,金属支架组与JJ支架组相比,估计重复手术干预减少了约4次,成本降低了23.4%。成本和收益的平均估算结果表明,使用 Resonance 治疗 MUO 5 年比使用 JJ 支架更有优势。据估计,5 年内每位患者可节省成本 2164.74 英镑,健康收益为质量调整生命年 (QALY) +0.046。根据每 QALY 2 万英镑的最大支付意愿,估计净货币收益 (NMB) 为 3077.83 英镑。在 20 000 英镑的支付意愿阈值下进行的概率敏感性分析表明,与 JJ 支架相比,Resonance 具有成本效益的概率为 89.3%。共振金属支架治疗 MUO 可减少重复手术次数,是一种具有成本效益的治疗方案,可为医疗系统带来潜在效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
Issue Information Issue Information Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1